LiDCO Group PLC (LON:LID) Investors: finnCap Reconfirms Corporate Rating, Sees GBX 14.00/Share; Hawkins Has 1.47 Sentiment

February 15, 2018 - By Annabelle Johnson

Hawkins, Inc. blends, manufactures, and distributes chemicals and specialty ingredients primarily in the United States. The company has market cap of $382.89 million. It operates in three divisions: Industrial, Water Treatment, and Health and Nutrition. It has a 11.73 P/E ratio. The Industrial segment provides industrial chemicals, products, and services primarily to the agriculture, chemical processing, electronics, energy, food, pharmaceutical, plating, and power generation industries.

LiDCO Group PLC (LON:LID) had its stock rating noted as Corporate by analysts at finnCap. finnCap currently has a GBX 14.00 TP on the 17.09 million GBP market cap company or 89.70% upside potential. This was released in an analyst note on Thursday, 15 February.

Martin & Co Inc Tn holds 0.45% of its portfolio in Hawkins, Inc. for 33,745 shares. Teton Advisors Inc. owns 105,600 shares or 0.4% of their US portfolio. Moreover, Northrock Partners Llc has 0.37% invested in the company for 23,476 shares. The Wisconsin-based Morgan Dempsey Capital Management Llc has invested 0.2% in the stock. Cutter & Co Brokerage Inc., a Missouri-based fund reported 10,030 shares.

The stock increased 1.42% or $0.5 during the last trading session, reaching $35.8. About 29,408 shares traded. Hawkins, Inc. (HWKN) has risen 30.55% since February 15, 2017 and is uptrending. It has outperformed by 13.85% the S&P500.

Since January 1, 0001, it had 0 buys, and 1 insider sale for $9,678 activity.

The stock decreased 5.08% or GBX 0.38 during the last trading session, reaching GBX 7. About 60,000 shares traded. LiDCO Group plc (LON:LID) has 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.

LiDCO Group Plc develops, manufactures, and sells cardiac monitoring equipment in the United Kingdom, the United States, Continental Europe, Japan, and internationally. The company has market cap of 17.09 million GBP. The firm offers LiDCOplus, a computer platform monitor, which is used in the intensive care unit for real-time continuous display of hemodynamic parameters, such as cardiac output, oxygen delivery, and fluid-volume responsiveness; and LiDCOrapid, a cardiac output monitor for use in the operating theatre and peri-operative arenas for fluid and drug management. It currently has negative earnings. It also provides LiDCOview, an easy-to-use graphical display of historical hemodynamic data that is used for research and education purposes; and LiDCOunity, a monitoring system, which enables clients to have seamless monitoring from the emergency department to the intensive care unit, and the operating room to high dependency units.